Could cause temporary or reversible harm; serious harm is unlikely.
Failed Impurities/Degradation Specifications: an out of specification result observed in degradation product test (any unspecified degradation product) during 18-month long term stability study.
| Brand name | CLOMIPRAMINE HYDROCHLORIDE |
| Generic name | CLOMIPRAMINE HYDROCHLORIDE CAPSULES |
| Active ingredient(s) | CLOMIPRAMINE HYDROCHLORIDE |
| Distributed by / for | Lupin Pharmaceuticals, Inc., Baltimore, MD 21202, United States |
| NDC | 68180-492-01 |
| Full product label | clomiPRAMINE hydrochloride Capsules USP, 25 mg, 100-count bottle, Rx only, Manufactured For: Lupin Pharmaceuticals, Inc., Baltimore, MD 21202, United States, Manufactured By: Lupin Limited, Nagpur, 441 108 INDIA, NDC 68180-492-01 |
| Recalling firm | Lupin Pharmaceuticals Inc. |
| Distribution | USA nationwide |
| Quantity | 2724 bottles |
| Recall initiated | 2025-04-10 |
| Report date | 2025-04-30 |
| Recall completed | 2026-01-05 |
| Recall number | D-0377-2025 |
| Classification | Class II |
| FDA status | Terminated |
| Origin on file | Naples FL United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗